Predictors of Kidney Outcomes of Anti-Glomerular Basement Membrane Disease in a Large Chinese Cohort.


Journal

American journal of nephrology
ISSN: 1421-9670
Titre abrégé: Am J Nephrol
Pays: Switzerland
ID NLM: 8109361

Informations de publication

Date de publication:
2022
Historique:
received: 09 10 2021
accepted: 11 02 2022
pubmed: 25 4 2022
medline: 16 6 2022
entrez: 24 4 2022
Statut: ppublish

Résumé

Anti-glomerular basement membrane (GBM) disease is a rare but the most aggressive form of glomerulonephritis. To dissect the prognostic factors, we retrospectively analyzed the clinical features of a large cohort and compared the clinical features and prognosis during decades. Data on clinical manifestation, treatment, and prognosis were collected. Cox models and receiver operating characteristic (ROC) curve were used to investigate the predictors for outcomes. The Kaplan-Meier curve and log-rank test were used to compare kidney and patient survival. A total of 448 patients were enrolled. Patient survival and kidney survival at 1 year was 69.4% and 37.7%, respectively. During the past 3 decades, mortality at 3 months and 1 year significantly dropped from 37.5% and 57.1% in 1991-2000 to 2.8% and 6.9% in 2011-2020 (p < 0.001), respectively; kidney prognosis showed a tendency of improvement as well. Serum creatinine (Scr) on diagnosis (HR, 1.16; 95% CI, 1.05-1.29) and crescent percentage (HR, 1.73; 95% CI, 1.34-2.24) were independent predictors for end-stage kidney disease. ROC curve showed that the optimal cutoff point of Scr on diagnosis for prediction of dialysis dependency at 1 year was 536.4 μmol/L (sensitivity 88.3% and specificity 80.8%). Antineutrophil cytoplasmic antibodies (ANCAs) positivity (HR, 4.43; 95% CI, 1.72-11.38) was a predictor for mortality. Plasma exchange was associated with a better patient prognosis (HR, 0.40; 95% CI 0.16-0.95). Scr on diagnosis and percentage of crescents were predictors for kidney outcomes. Positive ANCA was a predictor for mortality. Overall patient prognosis of anti-GBM disease was improved during the past 3 decades.

Identifiants

pubmed: 35462364
pii: 000523713
doi: 10.1159/000523713
doi:

Substances chimiques

Antibodies, Antineutrophil Cytoplasmic 0
Autoantibodies 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

397-406

Informations de copyright

© 2022 S. Karger AG, Basel.

Auteurs

Xiao-Yan Jia (XY)

Renal Division, Peking University First Hospital, Beijing, China, jiaxiaoyan1982@163.com.
Institute of Nephrology, Peking University, Beijing, China, jiaxiaoyan1982@163.com.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China, jiaxiaoyan1982@163.com.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China, jiaxiaoyan1982@163.com.
Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China, jiaxiaoyan1982@163.com.
Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China, jiaxiaoyan1982@163.com.
Department of Nephrology, Shandong Provincial Qianfoshan Hospital, Shandong Provincial Insititute of Nephrology, Jinan, China, jiaxiaoyan1982@163.com.

Hui-Yan Xu (HY)

Renal Division, Peking University First Hospital, Beijing, China.
Institute of Nephrology, Peking University, Beijing, China.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.
Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.
Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.
Department of Nephrology, Shandong Provincial Qianfoshan Hospital, Shandong Provincial Insititute of Nephrology, Jinan, China.

Xiao-Yu Jia (XY)

Renal Division, Peking University First Hospital, Beijing, China.
Institute of Nephrology, Peking University, Beijing, China.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.
Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.

Zhao Cui (Z)

Renal Division, Peking University First Hospital, Beijing, China.
Institute of Nephrology, Peking University, Beijing, China.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.
Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.

Ming-Hui Zhao (MH)

Renal Division, Peking University First Hospital, Beijing, China.
Institute of Nephrology, Peking University, Beijing, China.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.
Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.
Peking-Tsinghua Center for Life Sciences, Beijing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH